At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Buspirone as a Candidate Medication for Methamphetamine Abuse
In Brief
A Phase 1 clinical trial evaluating Methamphetamine and Placebo for Methamphetamine Dependence and Methamphetamine Abuse. Completed, enrolled 9 participants across 1 site.
Detailed Summary
Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of methamphetamine. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate the reinforcing effects of methamphetamine.
Study Details
Timeline
Interventions
The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.